COMMUNIQUÉS West-GlobeNewswire

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

05/09/2024 - 18:12

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

05/09/2024 - 18:00

COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

05/09/2024 - 17:54

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides [...]

New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024

05/09/2024 - 17:45

Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s [...]

BioNTX Unveils 2024 Rising Stars at the iC³® Life Science & Healthcare Innovation Summit

05/09/2024 - 17:06

IRVING, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- As Texas continues to grow as a biotech and healthcare innovative hub, BioNTX is honored to announce the 2024 Rising Stars, a select group of pioneering companies that [...]

Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results

05/09/2024 - 16:52

Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 ( Study Record | ClinicalTrials.gov ), an [...]

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 16:35

PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that [...]

Acentra Health Awarded a $298 Million Contract Renewal from the Centers for Medicare & Medicaid Services to Continue Improving Care Quality for Medicare Beneficiaries

05/09/2024 - 15:53

The company has established the largest geographic footprint of any CMS-contracted partner for beneficiary and family centered care-quality improvement services, serving Medicare enrollees across 29 states MCLEAN, Va., [...]

Pheton Holdings Ltd Announces Pricing of Initial Public Offering

05/09/2024 - 15:31

BEIJING, China, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products [...]

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 15:10

CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

05/09/2024 - 15:00

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review [...]

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

05/09/2024 - 15:00

CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per [...]

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

05/09/2024 - 15:00

Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( [...]

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

05/09/2024 - 15:00

GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation [...]

Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

05/09/2024 - 15:00

TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]

Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024

05/09/2024 - 15:00

AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data [...]

Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

05/09/2024 - 15:00

PALO ALTO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:45

LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the [...]

TerrAscend to Participate in the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference on September 18th in NYC

05/09/2024 - 14:30

TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that its executive management team will [...]